{"id":"da-2811","rwe":[{"pmid":"37113469","year":"2023","title":"A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects.","finding":"","journal":"Drug design, development and therapy","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Dong-A ST Co., Ltd.","category":"company"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Dong-A ST Co., Ltd.","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=DA-2811","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:53:00.772748+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:53:06.023552+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DA-2811","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:53:06.413652+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL578465/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:53:07.370875+00:00"}},"allNames":["da-2811"],"offLabel":[],"synonyms":[],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Da-2811 is a small molecule that likely interacts with a specific target through non-covalent binding, potentially altering the target's activity or expression."},"commercial":{},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=da-2811","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=da-2811","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-31T10:35:57.976916","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:53:08.965723+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"da-2811","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07239440","phase":"PHASE2","title":"Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing BT-1 and BT-2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control","status":"NOT_YET_RECRUITING","sponsor":"Dong-A ST Co., Ltd.","startDate":"2025-11","conditions":["Diabete Mellitus"],"enrollment":288,"completionDate":"2027-06"},{"nctId":"NCT05743907","phase":"PHASE4","title":"Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2023-04-25","conditions":["Diabetes Mellitus"],"enrollment":231,"completionDate":"2025-03-10"},{"nctId":"NCT04938752","phase":"PHASE1","title":"Pharmacokinetics and Safety/Tolerability Profiles of DA-2811 in Healthy Subjects (DA-2811)","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2021-07-08","conditions":["Healthy"],"enrollment":30,"completionDate":"2021-08-20"},{"nctId":"NCT04473417","phase":"PHASE1","title":"Pharmacokinetics and Safety/Tolerability Profiles of DA-2811 in Healthy Subjects","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2020-08-04","conditions":["Healthy"],"enrollment":60,"completionDate":"2020-10-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"chemblId":"CHEMBL578465"},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Dong-A ST Co., Ltd.","relationship":"Original Developer"}],"publicationCount":1,"therapeuticAreas":["Other"],"biosimilarFilings":[],"originalDeveloper":"Dong-A ST Co., Ltd.","recentPublications":[{"date":"2023","pmid":"37113469","title":"A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects.","journal":"Drug design, development and therapy"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"DA-2811","companyName":"Dong-A ST Co., Ltd.","companyId":"dong-a-st-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:53:08.965723+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}